Evidence map›Paper›PMID 35126729›Full record

ArticleOncology letters2022

Investigation of miRNA expression profiles using cohort samples reveals potential early detectability of colorectal cancers by serum miR-26a-5p before clinical diagnosis.

Asahi Hishida, Hiroya Yamada, Yoshitaka Ando, Yoshinaga Okugawa, Manabu Shiozawa, Yohei Miyagi, Yataro Daigo, Yuji Toiyama, Yumiko Shirai, Koji Tanaka and 9 more

Abstract read
In one paragraph

Article in Oncology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. AmiCa: Atlas of miRNA-gene correlations in cancer.Computational and structural biotechnology journal · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Asahi HishidaDepartment of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan.
Hiroya YamadaDepartment of Hygiene, Fujita Health University School of Medical Sciences, Toyoake, Aichi 470-1192, Japan.
Yoshitaka AndoDepartment of Informative Clinical Medicine, Fujita Health University School of Medical Sciences, Toyoake, Aichi 470-1192, Japan.
Yoshinaga OkugawaDepartment of Genomic Medicine, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan.
Manabu ShiozawaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center Hospital, Yokohama, Kanagawa 241-8515, Japan.
Yohei MiyagiMolecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa 241-8515, Japan.
Yataro DaigoCenter for Antibody and Vaccine Therapy, Institute of Medical Science, Research Hospital, The University of Tokyo, Tokyo 108-8639, Japan.
Yuji ToiyamaDepartment of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan.
Yumiko ShiraiDepartment of Nutrition, Iga City General Hospital, Iga, Mie 518-0823, Japan.
Koji TanakaDepartment of Surgery, Iga City General Hospital, Iga, Mie 518-0823, Japan.
Yoko KuboDepartment of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan.
Rieko OkadaDepartment of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan.
Mako NagayoshiDepartment of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan.
Takashi TamuraDepartment of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan.
Atsuyoshi MoriSeirei Preventive Health Care Center, Hamamatsu, Shizuoka 433-8558, Japan.
Takaaki KondoDepartment of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan.
Nobuyuki HamajimaDepartment of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan.
Kenji TakeuchiDepartment of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan.
Kenji WakaiDepartment of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies have investigated the usefulness of microRNA (miRNA/miR) expression data for the early detection of colorectal cancer (CRC). However, limited data are available regarding miRNAs that detect CRC before clinical diagnoses. Accordingly, the present study investigated the early detectability of CRC by miRNAs using the preserved serum samples of the cohort participants affected with CRC within 2 years of study enrollment. First, the significant miRNAs were revealed using clinical CRC samples for a (seven early CRCs and seven controls) microarray analysis based on significance analysis of microarrays. Next, replicability was verified by reverse transcription-quantitative (RT-q)PCR (eight early CRCs and eight controls, together with 12 CRCs and 12 controls). Finally, early detectability was tested using the cohort samples of Japan Multi-Institutional Collaborative Cohort Study (17 CRCs and 17 controls) to reveal how a certain number of patients developed CRC within 2 years after participation. In the discovery phase, miRNA expression measurements were conducted using a 3D-Gene Human miRNA Oligo Chip for 2,555 miRNAs, and RT-qPCR analyses were performed to validate the replicability. In the first validation set with eight CRCs with early clinical stage and eight age- and gender-matched controls, miR-26a-5p and miR-223-3p demonstrated the highest diagnostic accuracy of area under the curve (AUC)=1.000 (sensitivity and specificity 100%). In an examination of the predictability of CRC incidence using pre-clinical cohort samples, miR-26a-5p demonstrated good predictability of advanced CRC incidence with an AUC of 0.840. Overall, the present study revealed serum miR-26a-5p as a potential early detection marker for CRC.

Indexed as

cohort studycolorectal cancerearly detection of cancermicroRNA

Identifiers

PMID35126729
PMCPMC8805182

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.